Carbapenem-Resistant *Enterobacteriaceae* in Children, United States, 1999–2012

Technical Appendix

Technical Appendix Table 1. Tw	vo-vear CRE isolate counts by species.	the Surveillance Network-USA database,	1999–2012*

Organism	1999–2000	2001–2002	2003–2004	2005–2006	2007–2008	2009–2010	2011-2012
Enterobacter species†	0	1	6	2	20	23	46
Escherichia coli	0	0	1	1	12	16	28
Klebsiella pneumoniae	0	0	5	4	14	35	25
Serratia marcescens	0	0	0	0	3	3	11
Citrobacter species‡	0	0	0	0	0	5	3
Proteus mirabilis	0	0	0	0	0	0	2

*CRE, carbapenem-resistant Enterobacteriaceae. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptiblity to >1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem

nonsusceptibility (*P. mirabilis*), the CRE criteria required nonsusceptibility to ≥2 of the carbapenems listed.

†E. aerogenes and E. cloacae.

‡C. freundii and C. koseri.

	No. (%) isolates tested,	No. (%) CRE isolates tested,	No. CRE/no. tested, %,	
Characteristic	n = 8,319	n = 70	70/8,319 (0.84%)	
Organism				
Escherichia coli	4,733 (56.89)	4 (5.71)	0.08	
Klebsiella pneumonia	1,302 (15.65)	17 (24.29)	1.31	
Enterobacter species†	1,298 (15.60)	41 (58.57)	3.16	
Serratia marcescens	448 (5.39)	4 (5.71)	0.89	
Citrobacter species‡	274 (3.29)	4 (5.71)	1.46	
Proteus mirabilis	264 (3.17)	0	0.00	
Health care setting				
Outpatient	3,869 (46.51)	17 (24.29)	0.44	
Inpatient	2,543 (30.57)	27 (38.57)	1.06	
Inpatient-ICU	1,887 (22.68)	26 (37.14)	1.38	
Nursing home	12 (0.14)	0	0.00	
Unknown	8 (0.10)	0	0.00	
Isolate source				
Urine	4,860 (58.42)	32 (45.71)	0.66	
Lower respiratory tract	1,673 (20.11)	30 (42.86)	1.79	
Wound	921 (11.07)	7 (10.00)	0.76	
Blood	548 (6.59)	1 (1.43)	0.18	
Other§	317 (3.81)	0	0.00	
Sex				
F	4,197 (50.45)	28 (40.00)	0.67	
Μ	4,106 (49.36)	42 (60.00)	1.02	
Unknown	16 (0.19)	0	0.00	
Region				
South Atlantic	2,754 (33.10)	21 (30.00)	0.76	
West	2,015 (24.22)	14 (20.00)	0.69	
South Central	1,228 (14.76)	7 (10.00)	0.57	
West North Central	966 (11.61)	11 (15.71)	1.14	
East North Central	755 (9.08)	16 (22.86)	2.12	
North East	601 (7.22)	1 (1.43)	0.17	

Technical Appendix Table 2. Characteristics of *Enterobacteriaceae* isolates and children >1 year of age from which they were isolated, The Surveillance Network–USA database, 1999–2012*


*CRE, carbapenem-resistant *Enterobacteriaceae*. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptibility to \geq 1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem nonsusceptibility (*P. mirabilis*), the CRE criteria required nonsusceptibility to \geq 2 of the carbapenems listed. ICU, intensive care unit.

 \pm +Isolates were tested against \geq 1 third-generation cephalosporin and \geq 1 carbapenem of those considered for the CRE phenotype.


†E. aerogenes and E. cloacae.

‡C. freundii and C. koseri.


§Includes upper respiratory tract and skin cultures.



Technical Appendix Figure 1. Patient sex and national trends in prevalence of third-generation cephalosporin– and carbapenem-resistant *Enterobacteriaceae* (CRE) isolates from children, The Surveillance Network–USA database, 1999–2012. Data for patients <1 year of age were not available for all years and were excluded from analysis. There was a significant positive quadratic trend for male patients ($p = 3.4 \times 10^{-19}$) and female patients ($p = 2.5 \times 10^{-25}$).



Technical Appendix Figure 2. Isolate source and national trends in prevalence of third-generation cephalosporin– and carbapenem-resistant *Enterobacteriaceae* (CRE) isolates from children, The Surveillance Network–USA database, 1999–2012. Data for patients <1 year of age were not available for all years and were excluded from analysis. There was a positive quadratic trend for urine ($p = 3.1 \times 10^{-29}$), blood ($p = 2.0 \times 10^{-10}$), wound ($p = 1.1 \times 10^{-11}$), and lower respiratory tract ($p = 7.4 \times 10^{-6}$).



Technical Appendix Figure 3. Age group and national trends in prevalence of third-generation cephalosporin– and carbapenem-resistant *Enterobacteriaceae* (CRE) isolates from children, The Surveillance Network–USA database, 1999–2012. Data for patients <1 year of age were not available for all years and were excluded from analysis. There was a significant positive quadratic trend for ages 1–5 (p = 1.3×10^{-20}), 6–12 (p = 1.2×10^{-14}), and 13–17 years (p = 1.8×10^{-9}).